The molecular defect predisposing to the majority ofmalignant hyperthermia (MH) cases is unknown, although various point mutations in the ryanodine receptor gene (RYR1) have been associated with susceptibility in a small proportion of cases. We report here that one of these, the Argl63Cys substitution, does not cosegregate with MH susceptibility. Comparison of cDNA sequences encoding the skeletal muscle specific components of the dihydropyridine receptor a, subunit between MH susceptible (MHS) and MH non-susceptible (MHN) patients was made in subjects without the reported MH linked RYRI mutations. There were no differences within the sequence encoding the 11-III loop or the IS31IS3-IS4 segment, excluding defects in these functional segments of the a, subunit as frequent causes of MH.
Malignant hyperthermia (MH) presents clinically as a life threatening complication of anaesthesia and occurs in subjects with an underlying skeletal muscle disorder which is usually inherited as an autosomal dominant defect. ' Biochemical studies indicate that the primary defect in MH muscle lies in the regulation of calcium release from the sarcoplasmic reticulum (SR) membrane. The dihydropyridine receptor complex (DHPR) of the transverse tubule membrane and the ryanodine receptor (RYRI) was no evidence of polymorphism in the 11 subjects examined, establishing the sequence of this segment of the human gene (GenBank Accession Number U14413). The cDNA sequence of the IS3/IS3-S4 linker segment (GenBank Accession Number U18986) in five unrelated MHS patients and in four MHN Q controls also showed no differences between subjects. The sizes of these samples ensure, with an 85% and 90% probability respectively, 7r) that all polymorphisms with a frequency above -I-10% in these cDNA segments would have been shown by our analysis. 
